Vivistim System
Mobia Medical, Inc. · Decision date Apr 10, 2026
What did the FDA decide?
FDA records P210007/S013 as a supplement to PMA P210007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 10, 2026.
FDA approval order statement
Approval for supplier change
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Physical Medicine
- Decision date
- Apr 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210007/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- Decision code
- OK30
- Decision date
- Apr 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210007. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210007 · Original PMA
Vivistim System
P210007/S007 · Related supplement
Vivistim System
P210007/S010 · Related supplement
Vivistim System
P210007/S008 · Related supplement
Vivistim Paired VNS System
P210007/S011 · Related supplement
Vivistim System
P210007/S013 received
Application receipt date recorded by FDA.
P210007/S012 · Related supplement
Vivistim Paired VNS System
P210007/S013 · FDA decision
30-Day Notice
P210007/S014 · Related supplement
Vivistim Pair VNS System
P210007/S015 · Related supplement
Vivistim System
Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vivistim SystemP210007 | Mobia Medical, Inc. | PMA approval | Aug 27, 2021 | FDA |
Vivistim SystemP210007/S007 | Mobia Medical, Inc. | PMA supplement | Sep 3, 2025 | FDA |
Vivistim SystemP210007/S010 | Mobia Medical, Inc. | PMA supplement | Jan 28, 2026 | FDA |
Vivistim Paired VNS SystemP210007/S008 | Mobia Medical, Inc. | PMA supplement | Feb 26, 2026 | FDA |
Vivistim SystemP210007/S011 | Mobia Medical, Inc. | PMA supplement | Mar 2, 2026 | FDA |
Vivistim Paired VNS SystemP210007/S012 | Mobia Medical, Inc. | PMA supplement | Apr 1, 2026 | FDA |
Vivistim Pair VNS SystemP210007/S014 | Mobia Medical, Inc. | PMA supplement | Jun 18, 2026 | FDA |
Vivistim SystemP210007/S015 | Mobia Medical, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Mobia Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2802 Flintrock Trace, Suite 226, Austin, TX, 78738
Sources and methodology
- Original FDA record: P210007/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



